Biochemical pathways of metabolic disorders in psoriasis

Biochemical pathways of metabolic disorders in psoriasis

Автор: Samburskaya O.V., Kalinchenko S. Yu., Batkaeva N.V.

Журнал: Juvenis scientia @jscientia

Рубрика: Обзорные статьи

Статья в выпуске: 6 т.7, 2021 года.

Бесплатный доступ

The development of metabolic disorders occurs in psoriasis: insulin resistance, systemic inflammation, atherosclerosis, oxidative stress and obesity. The paper presents pathological biochemical pathways of metabolic disorders development which is caused by common cytokine profile chara-cteristic for psoriasis and obesity and they are tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and interleukin-8 (IL-8). The following links play a role in the development of insulin resistance: insulin receptor (IRS-1) and insulin receptor substrate (SIR-1), glucose transporter protein (GLUT-4), also there is a decrease in the phosphatidylinositol 3-kinase pathway (PI3AKT) activity, and an increase in the mitogen activating protein kinase (MAPK) activity. Factors influencing the development of inflammation are discussed: IL-6, C-reactive protein, tissue plasminogen activator inhibitor (PAI-1), monocyte chemoattractant protein 1 (MCP-1), proinflammatory adipokines; processes of vascular inflammation development, atherosclerosis development and oxidative stress. This article discusses endocrine disruption of adipocytes in obesity and the influence of adipokines and inflammatory mediators synthesized by fat cells on psoriatic disease. Advanced glycation end products (AGEs), hyperhomocysteinemia (HHcy) due to vitamin B12 and folic acid deficiency, and a 5,10-methylfolate reductase (MTHFR) mutation are also important in the clinical manifestations of psoriasis. The possibility of assessing metabolic disorders and dysfunction of various organs by changes in the levels of metabolites in the blood and skin of patients with psoriasis is discussed.

Еще

Adipocyte, adipokine, vitamin b12, vitamin d, inflammation, insulin resistance, metabolomics, oxidative stress, end-glycation products, psoriasis, folic acid

Короткий адрес: https://sciup.org/14123690

IDR: 14123690   |   DOI: 10.32415/jscientia_2021_7_6_6-16

Список литературы Biochemical pathways of metabolic disorders in psoriasis

  • Molochkov VA, Badokin VV, Albanova VI, et al. Psoriasis and psoriatic arthritis. Moscow: KMK Scientific Publishers Association. Author's Academy, 2007. P. 300. (in Russ.). [Молочков В.А., Бадокин В.В., Альба-нова В.И., и др. Псориаз и псориатический артрит. М.: Товарищество научных изданий КМК. Авторская академия, 2007. 300 c.]
  • Rasin MS. Chronic inflammation, insulin resistance, psoriasis — which have in common? Vestnik Dermatologii i Venerologii. 2016;(5):20-24. (in Russ.). [Расин М.С. Хроническое воспаление, инсулинорезистент-ность, псориаз — что общего?// Вестник дерматологии и венерологии 2016. № 5. С. 20-24.]
  • Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205-212. DOI: 10.im/jdv.13854
  • Burden-Teh E, Thomas KS, Ratib S, et al. The epidemiology of childhood psoriasis: a scoping review. Br JDermatol. 2016;174(6):1242-1257. DOI: 10.1111/bjd.14507
  • Gromova OA, Torshin lYu. Vitamin D: a paradigm shift. Moscow: Geotar-Media, 2018. P. 568. (in Russ.). [Громова О.А., Торшин И.Ю. Витамин D: смена парадигмы. М.: Гэотар-Медиа, 2018. 568 с.]
  • Boytsov SA, Strazhesko ID, Akasheva DU, et al. Insulin Resistance: Good or Bad? Development Mechanisms and the Association with Age-Related Vascular Changes. Cardiovascular Therapy and Prevention. 2013;12(4):91-97 (in Russ.). DOI: 10.15829/1728-8800-2013-4-91-97. [Бойцов С.А., Стражеско И.Д., Акашева Д.У., и др. Инсулинорезистентность: благо или зло? Механизмы развития и связь с возраст-ассоциирован-ными изменениями сосудов // Кардиоваскулярная терапия и профилактика. 2013. Т. 12. № 4. С. 91-97.]
  • Bronckers IM, Paller AS, van Geel MJ, et al. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatr Drugs. 2015;17(5):373-384. DOI: 10.1007/s40272-015-0137-1
  • Demidova TYu. Etiopthogenic Role of Insulin Resistance in the Development of Metabolic and Vascular Disorders in Type 2 Diabetes Mellitus. Farmateka. 2010;(16):18-24. (in Russ.). [Демидова Т.Ю. Этиопато-генетическая роль инсулинорезистентности в развитии метаболических и сосудистых нарушений при сахарном диабете типа 2 // Фарматека. 2010. № 16(210). С. 18-24.]
  • Taganovich AD, Oletsky EI, Kotovich IL. Pathological Biochemistry. Moscow: BINOM Publisher, 2019. 448 pp. (in Russ.). [Таганович А.Д., Олецкий Э.И., Котович И.Л. Патологическая биохимия. М.: Издательство БИНОМ, 2019. 448 с.]
  • Szymczak-Pajor I, Drzewoski J, Sliwinska A. The Molecular Mechanisms by Which Vitamin D Prevents Insulin Resistance and Associated Disorders. Int J Mol Sci. 2020;21(18):6644. DOI: 10.3390/ijms21186644
  • Kong Y, Zhang S, Wu R, et al. New insights into different adipokines in linking the pathophysiology of obesity and psoriasis. Lipids Health Dis. 2019;18(1):171. DOI: 10.1186/s12944-019-1115-3
  • Ivashkin VT, Drapkina OM, Korneeva ON. Clinical variants of metabolic syndrome. Moscow: Medical Information Agency, 2012. 212 pp. (in Russ.). [Ивашкин В.Т., Драпкина О.М., Корнеева О.Н. Клинические варианты метаболического синдрома. М.: Медицинское информационное агентство, 2012. 212 с.]
  • Pujari VM, Suryakar AN, Ireddy S. Oxidants and antioxidant status in psoriasis patients. Biomedical Research. 2010;21(2):221-223.
  • Zhang Y, Li Z, Ma Y, Mu Z. Association of total oxidant status, total antioxidant status, and malondialdehyde and catalase levels with psoriasis: a systematic review and meta-analysis. Clin Rheumatol. 2019;38(10):2659-2671. DOI: 10.1007/s10067-019-04676-1
  • Tollefson MM, Van Houten HK, Asante D, et al. Association of Psoriasis With Comorbidity Development in Children With Psoriasis. JAMA Dermatol. 2018;154(3):286-292. DOI: 10.1001/jamadermatol.2017.5417
  • Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633-636. DOI: 10.1111/j.1365-2133.2009.09593.x
  • Bronckers IM, Paller AS, van Geel MJ, et al. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatr Drugs. 2015;17(5):373-384. DOI: 10.1007/s40272-015-0137-1
  • Becker L, Tom WL, Eshagh K, et al. Excess adiposity preceding pediatric psoriasis. JAMA Dermatol. 2014;150(5):573-574. DOI: 10.1001/jamadermatol.2014.324
  • Han JH, Lee JH, Han KD, et al. Increased risk of psoriasis in subjects with abdominal obesity: A nationwide population-based study. J Dermatol. 2019;46(8):695-701. DOI: 10.1111/1346-8138.14939
  • Potemkin VV. Endocrinology: a guide for physicians. Moscow: Medical Information Agency, 2013. 771 pp. (in Russ.). [Потёмкин В.В. Эндокринология: руководство для врачей. М.: Медицинское информационное агентство, 2013. 771 с.]
  • Dedov II. Diseases of adipose tissue. Moscow: Geotar-Media, 2020. Р. 233. (in Russ.). [Дедов И.И. Болезни жировой ткани. М:. Гэотар-Медиа, 2020. 233 с.]
  • Lykova SA, Spitsina AV, Morzhanaeva MA. Metabolic Syndrome and Psoriasis are as Comorbidity States. Far Eastern Medical Journal. 2017;(1):93-98. (in Russ.). [Лыкова С.А., Спицина А.В., Моржанаева М.А. Метаболический синдром и псориаз как коморбидные состояния // Дальневосточный медицинский журнал. 2017. № 1. С. 93-98.]
  • Benzian-Olsson N, Dand N, Chaloner C, et al. Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. JAMA Dermatol. 2020;156(11):1216-1222. DOI: 10.1001/ jamadermatol.2020.3275
  • Lu C, He JC, Cai W, et al. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci U S A. 2004;101(32):11767-11772. DOI: 10.1073/pnas.0401588101
  • Emelyanov VV. Glycation, Antiglycation and Deglycation: Role in Mechanisms of Aging Ang Geroprotective (Literature Review). Advances in Gerontology. 2016;29(3):407-416. (in Russ.). [Емельянов В.В. Гликирова-ние, антигликирование и дегликирование: роль в механизмах старения и геропротекции (обзор литературы) // Успехи геронтологии. 2016. Т. 29. № 3. С. 407-416.]
  • Leonova TS, Vikhnina MV, Grishina TV, et al. Influence of Advanced Glycation end Products on Cellular Processes. International Research Journal. 2018;(12-1):185-194. DOI: 10.23670/IRJ.2018.78.12.034. (in Russ.). [Леонова Т.С., Вихнина М.В., Гришина Т.В, и др. Влияние конечных продуктов глубокого глики-рования на клеточные процессы // Международный научно-исследовательский журнал. 2018. № 12-1(78). С. 185-194.]
  • Lee EJ, Kim JY, Oh SH. Advanced glycation end products (AGEs) promote melanogenesis through receptor for AGEs. Sci Rep. 2016;6:27848. DOI: 10.1038/srep27848
  • Lykova SG, Svechnikova EV, Morzhanaeva MA. Advanced Glycation end Products as Biomarkers of Aging. Bulletin of the Russian Academy of Natural Sciences. 2018;18(2):71-77. (in Russ.). [Лыкова С.Г., Свечнико-ва Е.В., Моржанаева М.А. Конечные продукты гликирования как биомаркеры старения // Вестник Российской академии естественных наук. 2018. Т. 18. № 2. С. 71-77.]
  • Papagrigoraki A, Maurelli M, Del Giglio M, et al. Advanced Glycation End Products in the Pathogenesis of Psoriasis. Int J Mol Sci. 2017;18(11):2471. DOI: 10.3390/ijms18112471
  • Lian N, Shi LQ, Hao ZM, Chen M. Research progress and perspective in metabolism and metabolomics of psoriasis. Chin Med J (Engl). 2020;133(24):2976-2986. DOI: 10.1097/CM9.0000000000001242
  • Li SS, Liu Y, Li H, et al. Identification of psoriasis vulgaris biomarkers in human plasma by non-targeted metabolomics based on UPLC-Q-TOF/MS. Eur Rev Med Pharmacol Sci. 2019;23(9):3940-3950. DOI: 10.26355/eurrev_201905_17823
  • Wojcik P, Biernacki M, Wronski A, et al. Altered Lipid Metabolism in Blood Mononuclear Cells of Psoriatic Patients Indicates Differential Changes in Psoriasis Vulgaris and Psoriatic Arthritis. Int J Mol Sci. 2019;20(17):4249. DOI: 10.3390/ijms20174249
  • Chen C, Hou G, Zeng C, et al. Metabolomic profiling reveals amino acid and carnitine alterations as metabolic signatures in psoriasis. Theranostics. 2021;11(2):754-767. DOI: 10.7150/thno.51154
  • Ottas A, Fishman D, Okas TL, et al. The metabolic analysis of psoriasis identifies the associated metabolites while providing computational models for the monitoring of the disease. Arch Dermatol Res. 2017;309(7):519-528. DOI: 10.1007/s00403-017-1760-1
  • Pohla L, Ottas A, Kaldvee B, et al. Hyperproliferation is the main driver of metabolomic changes in psoriasis lesionalskin. Sci Rep. 2020;10(1):3081. DOI: 10.1038/s41598-020-59996-z
  • Lin X, Meng X, Song Z. Homocysteine and psoriasis. Biosci Rep. 2019;39(11):BSR20190867. DOI: 10.1042/ BSR20190867
  • Mashkileyson LN. Private Dermatology. Moscow: "Medicina" Publishing House, 1965. 522 pp. (in Russ.). [Машкилейсон Л.Н. Частная дерматология. М.: Издательство «Медицина», 1965. 522 с.]
  • Wang WM, Jin HZ. Homocysteine: A Potential Common Route for Cardiovascular Risk and DNA Methylation in Psoriasis. Chin Med J (Engl). 2017;130(16):1980-1986. DOI: 10.4103/0366-6999.211895
  • Beranek M, Malkova A, Fiala Z, et al. Goeckerman Therapy of Psoriasis: Genotoxicity, Dietary Micronutrients, Homocysteine, and MTHFR Gene Polymorphisms. Int J Mol Sci. 2019;20(8):1908. DOI: 10.3390/ijms20081908
  • Abedini R, Goodarzi A, Saeidi V, et al. Serum homocysteine level, vitamin B12 levels, and erythrocyte folate in psoriasis: A case-control study. Int J Womens Dermatol. 2019;5(3):171-174. DOI: 10.1016/j.ijwd.2018.12.004
  • Cakmak SK, Gül U, Kilig C, et al. Homocysteine, vitamin B12 and folic acid levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2009;23(3):300-303. DOI: 10.1111/j.1468-3083.2008.03024.x
  • Tsai TY, Yen H, Huang YC. Serum homocysteine, folate and vitamin B12 levels in patients with psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;180(2):382-389. DOI: 10.1111/bjd.17034
Еще
Статья обзорная
SciUp 2024 © 2024 ©